ASRS 2024: Sodium-Glucose Cotransporter 2 Inhibitors Tied to Lower Risk for Diabetic Retinopathy Versus Other Glucose-Lowering Agents
Glucagon-like peptide-1 receptor agonists do not increase retinal risk versus dipeptidyl peptidase-4 inhibitors, sulfonylureas
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.